QIAGEN(QGEN)

Search documents
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil's national screening programs
GlobeNewswire News Room· 2024-09-12 20:05
Venlo, the Netherlands, Rio de Janeiro, Brazil, Sept. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its strategic partnership with BioManguinhos/Fiocruz, the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinho ...
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
ZACKS· 2024-09-05 14:20
QIAGEN N.V. (QGEN) recently entered into a collaboration to support the development of a QIAstat-Dx invitro diagnostic (IVD) panel with Eli Lilly and Company. The QIAstat-Dx panel will be used to detect apolipoprotein E (APOE) genotypes. The QIAstat-Dx panel will be the first commercially available IVD for APOE genotyping. The recent collaboration is poised to enhance the company's Molecular Diagnostics business. Shares of QGEN were up 0.4% in pre-market trading today following the news. With the company ga ...
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer's disease
GlobeNewswire News Room· 2024-09-04 20:05
Venlo, the Netherlands, Sept. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes which can play a role in the diagnosis of Alzheimer's disease. This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping. The panel will be int ...
QIAGEN N.V. announces conversion price of new net share settled convertible bonds
GlobeNewswire News Room· 2024-09-03 21:05
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of the new senior ...
QIAGEN N.V. announces successful placement of new net share settled convertible bonds
GlobeNewswire News Room· 2024-09-03 15:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") announces certain terms of the new senior, unsecured net sha ...
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
GlobeNewswire News Room· 2024-09-03 06:36
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Managing Board and Supervisory Board of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") ...
Reasons to Retain QIAGEN Stock in Your Portfolio Now
ZACKS· 2024-08-27 14:55
QIAGEN N.V.'s (QGEN) growth is backed by its robust progress in expanding the test menu options. The company's expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to macroeconomic volatilities and currency fluctuations, which can adversely affect its financial results. Year to date, this Zacks Rank #3 (Buy) stock has risen 0.9% compared with 10.5% growth of the industry. The S&P 500 composite has witnessed an 18.1% rise in ...
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
ZACKS· 2024-08-22 14:55
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...
QIAGEN(QGEN) - 2024 Q2 - Quarterly Report
2024-08-02 01:07
Exhibit 99.7 QIAGEN N.V. IFRS Annual Report 2023 QIAGEN N.V. | IFRS Annual Report 2023 Overview Management Report Corporate Governance Financial Statements Appendices Page 2 Overview Table of Contents | --- | --- | --- | --- | |-------|------------------------------------------------------------|-------|-------------------------------------------------| | | | | Consolidated Financial Statements | | | Overview | 172 | Consolidated Balance Sheets | | 3 | Common Shares | 174 | Consolidated Income Statements | ...
QIAGEN(QGEN) - 2024 Q2 - Earnings Call Transcript
2024-08-01 19:04
Qiagen N.V. (NYSE:QGEN) Q2 2024 Earnings Call Transcript Q2 2024 Earnings Conference Call August 1, 2024 9:00 AM ET Company Participants John Gilardi - Investor Relations Thierry Bernard - Chief Executive Officer and Managing Director Roland Sackers - Chief Financial Officer and Managing Director Conference Call Participants Catherine Schulte - Baird Michael Ryskin - Bank of America Jack Meehan - Nephron Research Dan Arias - Stifel Odysseas Manesiotis - Berenberg Bank Douglas Schenkel - Wolfe Research Patri ...